Lacosamide

CHEMBL58323 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
250.3 g/mol
LogP
0.3
Phase
4

An anticonvulsant used as monotherapy or adjunctive treatment for focal seizures in adults and children with epilepsy. It works by enhancing the slow inactivation of sodium channels in neurons, reducing their ability to fire excessively.

आणविक भार

250.2900 g/mol

LogP

0.30

TPSA

67.40 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1

InChI

InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

Molecular Formula

C13H18N2O3

HBD / HBA

2 / 3

घूर्णनीय बंधन

6

भारी परमाणु

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An anticonvulsant used as monotherapy or adjunctive treatment for focal seizures in adults and children with epilepsy. It works by enhancing the slow inactivation of sodium channels in neurons, reducing their ability to fire excessively.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Lacosamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL58323. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 219078. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.